Fabry Disease Treatment Showdown: Protalix Bio’s Elfabrio joins the…
FDA approved Chiesi group And Protalix BioTherapeutics Inc PLX Elfabrio (pegunigalsidase alfa-iwxj) used to treat adults Patients with Fabry disease. The product is an enzyme replacement therapy for adults with a rare inherited disease in which abnormal deposits of lipids build up, causing pain and sometimes end-organ failure. Elfabrio is a PEGylated enzyme replacement therapy. […]
Ketamine Company Brings Parkinson’s Treatment To Its End Stages…
PharmaTher Holdings Ltd. PHRRF‘s recent meeting with the FDA on the feasibility of a Phase 3 program for proprietary ketamine KETARX for the treatment of levodopa-induced dyskinesia in Parkinson’s disease (LID-PD) was successful with federal agency support for the company’s overall approach. There is currently no cure for this progressive neurodegenerative disease, although some drug […]
Analyst Says Biogen-Eisai’s Alzheimer’s Treatment Leqembi Coverage…
Eisai Co Ltd ESALY And Biogen Inc BIIB said the U.S. Department of Veterans Affairs (VA) will provide early-stage information to veterans about their Alzheimer’s treatment Leqembi (lecanemab). A document shows that the FDA has added Leqembi and made it available subject to patients requesting it, obtaining prior approval, and meeting strict inclusion […]
Cannabis-based medicine as a potential treatment for psychosis, …
The University of Oxford’s Department of Psychiatry will conduct an international study to investigate whether cannabis-based medicine can treat psychosis. The study was funded by the charitable foundation with £16.5 million ($19.8 million). Welcome. It will include 35 centres, mostly in Europe and North America, and around 1,000 participants – including those at ‘clinically high […]
Armada Hoffler announces income tax treatment of its 2022 dividend
VIRGINIA BEACH, Va., Feb. 15, 2023 (GLOBE NEWSWIRE) — Armada Hoffler ahh announced the income tax treatment of its 2022 dividend distributions to holders of the Company’s common and preferred stock. This information represents final income allocations as reported on Form 1099-DIV. The tax information provided should not be construed as tax advice. Shareholders are […]
Awakns Ketamine Treatment For Alcohol Use Disorder With British…
Awakn Life Sciences Corp. AWKNF, a biotech company developing therapeutics to treat addictions with a near-term focus on Alcohol Use Disorders (AUD), has received an Innovation Passport for its proprietary Ketamine-Assisted Therapy (KAT) for treating severe AUD. The passport was issued by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). See also: Can Ketamine […]
Fanconi Anemia Treatment Market Research with Growth Analysis and…
Reports and Data’s latest market analysis report titled “‘Fanconi anemia treatment market – Forecast to 2030” is a comprehensive study of the Fanconi Anemia Treatment industry and provides the target audience with important data and information about the industry. The report encompasses quantitative and qualitative research of the Treatment of Fanconi Anemia market along with […]
Is the Psychedelic Treatment Around the Corner? MDMA for PTSD Checks…
MAPS Public Benefit Corporation (MAPS PBC), the nonprofit’s private biopharmaceutical arm that develops psychedelic drugs, announced positive results from the Company’s product, MAPP2 second phase 3 study evaluating MDMA-assisted therapy in PTSD. “The confirmatory Phase 3 results support the development of MDMA-assisted therapy as a potential new breakthrough therapy for the treatment of individuals with […]
Critical Limb Ischemia Treatment Market Recent Trends and Future…
That “Critical Limb Ischemia Treatment Market Forecast to 2028 – Covid-19 Impact and Global Analysis report added to Insight Partners has covered and analyzed the potential of Global Critical Limb Ischemia Treatment Market and provides statistics and information on market size, shares and growth factors. The report aims to provide up-to-date market information and help […]
Mestastop Solution case studies may change the paradigm of cancer treatment
From 2003 to 2021, for all 124 FDA-approved novel cancer drugs, the net improvement in mean overall survival (OS) and progression-free survival (PFS) was 2.8 and 3.3 months, respectively, for all solid cancers. These numbers reveal the stark reality of treating all solid tumors; Despite the era of targeted/precision medicine and immunotherapy, little progress has […]